A detailed history of Bank Of America Corp transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 42,297 shares of BDTX stock, worth $104,473. This represents 0.0% of its overall portfolio holdings.

Number of Shares
42,297
Previous 18,887 123.95%
Holding current value
$104,473
Previous $88,000 107.95%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.2 - $6.58 $98,322 - $154,037
23,410 Added 123.95%
42,297 $183,000
Q2 2024

Aug 14, 2024

BUY
$4.65 - $7.39 $34,930 - $55,513
7,512 Added 66.04%
18,887 $88,000
Q1 2024

May 15, 2024

SELL
$2.67 - $5.74 $121,642 - $261,508
-45,559 Reduced 80.02%
11,375 $57,000
Q4 2023

Feb 14, 2024

BUY
$1.77 - $3.03 $100,751 - $172,473
56,922 Added 474350.0%
56,934 $159,000
Q2 2023

Aug 14, 2023

SELL
$1.43 - $6.18 $18,271 - $78,961
-12,777 Reduced 99.91%
12 $0
Q1 2023

May 12, 2023

SELL
$1.35 - $3.14 $33 - $78
-25 Reduced 0.2%
12,789 $24,000
Q4 2022

Feb 10, 2023

SELL
$1.27 - $2.51 $2,885 - $5,702
-2,272 Reduced 15.06%
12,814 $23,000
Q3 2022

Nov 14, 2022

SELL
$1.68 - $4.01 $58,193 - $138,902
-34,639 Reduced 69.66%
15,086 $25,000
Q2 2022

Aug 12, 2022

SELL
$1.5 - $3.63 $12,771 - $30,905
-8,514 Reduced 14.62%
49,725 $122,000
Q1 2022

May 16, 2022

SELL
$2.66 - $5.61 $2,356 - $4,970
-886 Reduced 1.5%
58,239 $161,000
Q4 2021

Feb 08, 2022

BUY
$5.18 - $8.48 $113,799 - $186,297
21,969 Added 59.13%
59,125 $316,000
Q3 2021

Nov 15, 2021

SELL
$8.46 - $12.42 $81,858 - $120,175
-9,676 Reduced 20.66%
37,156 $314,000
Q2 2021

Sep 13, 2021

BUY
$12.19 - $28.17 $570,882 - $1.32 Million
46,832 New
46,832 $570,000

Others Institutions Holding BDTX

About Black Diamond Therapeutics, Inc.


  • Ticker BDTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,339,500
  • Market Cap $89.8M
  • Description
  • Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...
More about BDTX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.